Publications by authors named "J T M Burghouts"
Objectives: Acceptance of childhood vaccination varies between societies, affecting worldwide vaccination coverage. Low coverage rates are common in indigenous populations where parents often choose not to vaccinate their children. We aimed to gain insight into reasons for vaccine acceptance or rejection among Warao Amerindians in Venezuela.
View Article and Find Full Text PDFBackground And Objectives: In the EORTC ALL-3 trial, the efficacy of allogeneic transplantation was compared with that of autologous marrow transplantation and maintenance chemotherapy in patients
Design And Methods: Among 340 patients who entered the study, 279 were
Background: To determine whether the cost of prophylactic antibiotics during chemotherapy is offset by cost savings due to a decreased incidence of febrile leukopenia (FL).
Patients And Methods: Small-cell lung cancer (SCLC) patients were randomised to standard or intensified chemotherapy with granulocyte colony-stimulating factor to assess the impact on survival (n = 244). In addition, patients were randomised to prophylactic ciprofloxacin and roxithromycin or placebo to assess the impact on FL (n = 161).
Standard versus intensified chemotherapy with granulocyte colony-stimulating factor support in small-cell lung cancer: a prospective European Organization for Research and Treatment of Cancer-Lung Cancer Group Phase III Trial-08923.
J Clin Oncol
October 2002
Purpose: To assess the impact on survival of increasing dose-intensity (DI) of cyclophosphamide, doxorubicin, and etoposide (CDE) in small-cell lung cancer (SCLC).
Patients And Methods: Previously untreated SCLC patients were randomized to standard CDE (cyclophosphamide 1,000 mg/m(2) and doxorubicin 45 mg/m(2) on day 1, and etoposide 100 mg/m(2) on days 1 to 3 every 3 weeks, for five cycles) or intensified CDE (cyclophosphamide 1,250 mg/m(2) and doxorubicin 55 mg/m(2) on day 1, and etoposide 125 mg/m(2) on days 1 to 3 with granulocyte colony-stimulating factor [G-CSF] 5 micro g/kg/d on days 4 to 13 every 2 weeks, for four cycles). Projected cumulative dose was almost identical on the two arms, whereas projected DI was nearly 90% higher on the intensified arm.
Article Synopsis
- Prophylactic antibiotics significantly reduce the incidence of febrile leucopenia (FL) during CDE chemotherapy for small-cell lung cancer (SCLC), showing a decrease from 25% in the placebo group to 11% in the antibiotics group.
- Patients receiving antibiotics also experienced fewer infections overall and required less therapeutic antibiotics, resulting in fewer hospitalizations due to FL (31 vs. 17).
- The use of ciprofloxacin and roxithromycin led to no infectious deaths in the antibiotics group, whereas there were five deaths (6%) in the placebo group, indicating a substantial benefit in patient outcomes.